New Important Research Post for Leading Acneologist, Dr Alison Layton

YY Skincare Scientific Advisory Panel member, and globally renowned acneologist, Dr Alison Layton has just taken on another research role to add to her portfolio of “front line” clinical & scientific activities in the field of dermatology. From 1st September 2010 Alison will become the new Clinical Director of the North & East Yorkshire & North Lincolnshire Comprehensive Local Research Network.

Dr Layton is a Consultant Dermatologist, Trust R&D Lead and Associate Medical Director for Research at Harrogate and District NHS Foundation Trust. Appointed as Consultant Dermatologist at Harrogate and District NHS Foundation Trust in 1995, Dr Layton has established a comprehensive dermatology service and runs condition based clinics in acne, skin cancer and general dermatology. She has also introduced a novel cosmetic service with experienced colleagues, running in parallel with the NHS dermatology service, called “Foundation Skin”.  

Dr Layton has a particular interest in androgen mediated disorders including acne and polycystic ovary syndrome (PCOS) and as a consequence she sits on the Executive Council of PCOS UK, the European Expert and Global Alliance Panel for Acne.  Her expertise has attracted invitations to run many clinical trials investigating therapies for the common inflammatory dermatoses including acne, rosacea and psoriasis.

Alison is a member of the UK Dermatology Clinical Trials Network steering group. Her work has a particular focus on the basic science research investigating immunological and microbiological aspects of acne. In the process she has built up collaborations with the University of Leeds and School of Biology in York. It should be noted in this context that she wrote chapters for the eighth edition of Rook’s Textbook of Dermatology and for the Oxford Textbook of Medicine on “Disorders of Sebaceous glands”.

Once Alison is fully in her new post, she will be meeting with key stakeholders from the NEYNL CLRN Member Organisations, focusing on reviewing CLRN investment, infrastructure and performance. YY Skincare wishes her well in this new research role.